Abstract:

Tuberculosis is a kind of infectious disease caused by Mycobacterium tuberculosis complex group, which seriously endangers human health. On November 9, 2017, the National Health and Family Planning Commission issued the two mandatory health industry standards for Classification of tuberculosis (WS 196-2017) and Diagnosis for pulmonary tuberculosis (WS 288-2017), and will implement on May 1, 2018. At the same time, “Classification of tuberculosis (WS 196-2001)” and “Diagnosis for pulmonary tuberculosis (WS 288-2008)” will be abolished. In the standard of Diagnosis for pulmonary tuberculosis (WS 288-2017), the status of pathological diagnosis in tuberculosis diagnosis and precision treatment is significantly improved. Pulmonary tuberculosis can be diagnosed by pathological diagnosis. The findings of the imaging examination support the diagnosis of tuberculosis, while patients with positive molecular biology can also be diagnosed with tuberculosis. PCR technology can quickly diagnose Mycobacterium tuberculosis infection, the nucleic acid hybridization technique can quickly detect the mutation site of the gene and determine the type of drug resistance of Mycobacterium tuberculosis. Further study and implementation of the standard of Diagnosis for pulmonary tuberculosis (WS 288-2017) is of great importance to clarify and understand the role of pathological diagnosis in the clinical diagnosis and precise treatment of tuberculosis.

Key words: Tuberculosis, Pathology,clinical, Pathology,molecular, Molecular biology, Tuberculosis,multidrug-resistant